Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 19 (2005), Issue 10, Pages 625-629
http://dx.doi.org/10.1155/2005/378587
Brief Communication

Lamivudine for the Treatment of Membranous Glomerulopathy Secondary to Chronic Hepatitis B Infection

SI Gan,1 SM Devlin,1 NW Scott-Douglas,2 and KW Burak1,3

1Divisions of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
2Divisions of Nephrology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
3Liver Unit, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

Copyright © 2005 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Membranous glomerulopathy is a well-recognized extrahepatic manifestation of chronic hepatitis B virus (HBV) infection. The authors report two cases of HBV-related nephrotic syndrome treated with lamivudine. A 46-year-old Chinese man had a hepatitis B e antigen seroconversion along with improvement in his nephrotic syndrome after lamivudine therapy. Two years after treatment was discontinued, a reactivation of HBV was successfully treated again with lamivudine. A 44-year-old Chinese woman, who was intolerant of interferon, was treated with lamivudine for 15 months without a virological response. However, two years after completing lamivudine, her nephrotic syndrome resolved. Implications for the treatment of HBV-related glomerulopathy and a review of the literature are presented.